On March 12, 2013, Acadia Pharmaceuticals (ACAD) reported financial results for the fourth quarter and full year 2012. Total revenues in the quarter were $0.4 million, essentially in-line with our estimate of $0.3 million. Revenues consisted of collaborative payments from Allergan, Inc. (AGN) and other collaboration partners. For the full year 2012, total revenues were $4.9 million.
GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced that it has achieved ISO 13485 certification, the global standard for the requirements of a quality management system for the design, manufacture and distribution of medical devices. By establishing a quality management system that meets international regulatory and customer requirements, GlySure has set the foundation for its European clinical trials.
Aside from re-defined financing structures, the most important issue facing life sciences EGCs is the need to increase clinical trial efficiency and productivity so that development budgets are used prudently to support products that have the best chance of market success. Speaking to OneMedTV during OneMedForum this past January, Donnelly discussed current changes that will impact the future of product development and the central role that innovative trial design will play in this.
MediTech Strategic Consultants B.V. (MediTech) is full service European Contract Research Organization (CRO) specializing in medical devices and combination products focused on Clinical, Regulatory and Quality consulting as well as Authorized Representative Services.
Scientists have yet to find the magic cure for cancer, but they may have found a way to beat it at its own game.
Cardiovascular Systems, a medical device company that specializes in the treatment of vascular diseases, has enrolled the first patient in its COMPLIANCE 360° clinical trial.
FST-100 performed significantly better than other treatments for adenoviral conjunctivitis, including the current experimental “gold standard” topical cidofovir.
The money will allow CNS Response, based in Costa Mesa, Calif., to complete an upcoming depression study.
VIVUS, a pharmaceutical company specializing in products to treat sexual function, announced that their experimental obesity drug Qnexa was shown to improve blood sugar control in patients with type 2 diabetes.
A method of delivering chemotherapy drugs into a deadly type of brain tumor extended the lives of patients in early clinical trials.
Copyright © 2024 | WordPress Theme by MH Themes